BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 22971544)

  • 1. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Sleeman IJ; Boshoff EL; Duty S
    Neuropharmacology; 2012 Dec; 63(7):1268-77. PubMed ID: 22971544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor 20 is protective towards dopaminergic neurons in vivo in a paracrine manner.
    Boshoff EL; Fletcher EJR; Duty S
    Neuropharmacology; 2018 Jul; 137():156-163. PubMed ID: 29698669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation.
    Carbone M; Duty S; Rattray M
    BMC Neurosci; 2012 Apr; 13():38. PubMed ID: 22480308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adrenalectomy counteracts the local modulation of astroglial fibroblast growth factor system without interfering with the pattern of 6-OHDA-induced dopamine degeneration in regions of the ventral midbrain.
    Chadi G; Silva C; Maximino JR; Fuxe K; da Silva GO
    Brain Res; 2008 Jan; 1190():23-38. PubMed ID: 18086466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
    Afshin-Majd S; Bashiri K; Kiasalari Z; Baluchnejadmojarad T; Sedaghat R; Roghani M
    Biomed Pharmacother; 2017 May; 89():1-9. PubMed ID: 28199883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson's disease.
    Fletcher EJR; Moon LDF; Duty S
    BMC Neurosci; 2019 Dec; 20(1):61. PubMed ID: 31862005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hesperidin protects against behavioral alterations and loss of dopaminergic neurons in 6-OHDA-lesioned mice: the role of mitochondrial dysfunction and apoptosis.
    Antunes MS; Ladd FVL; Ladd AABL; Moreira AL; Boeira SP; Cattelan Souza L
    Metab Brain Dis; 2021 Jan; 36(1):153-167. PubMed ID: 33057922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects simultaneous inhibition of dipeptidyl peptidase-4 and P2X7 purinoceptors in an in vivo Parkinson's disease model.
    Jamali-Raeufy N; Mojarrab Z; Baluchnejadmojarad T; Roghani M; Fahanik-Babaei J; Goudarzi M
    Metab Brain Dis; 2020 Mar; 35(3):539-548. PubMed ID: 32016817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered melatonin MT
    Kang NH; Carriere CH; Bahna SG; Niles LP
    Brain Res; 2016 Dec; 1652():89-96. PubMed ID: 27693415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Protective effect of alkaloids from Piper longum in rat dopaminergic neuron injury of 6-OHDA-induced Parkinson's disease].
    Zheng L; Wang H; Ba YY; Liu HL; Wang M; Guo WW; Wu X; Yang H
    Zhongguo Zhong Yao Za Zhi; 2014 May; 39(9):1660-5. PubMed ID: 25095380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
    Rosenblad C; Kirik D; Björklund A
    Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acupuncture prevents 6-hydroxydopamine-induced neuronal death in the nigrostriatal dopaminergic system in the rat Parkinson's disease model.
    Park HJ; Lim S; Joo WS; Yin CS; Lee HS; Lee HJ; Seo JC; Leem K; Son YS; Kim YJ; Kim CJ; Kim YS; Chung JH
    Exp Neurol; 2003 Mar; 180(1):93-8. PubMed ID: 12668152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson's Disease.
    Barata-Antunes S; Teixeira FG; Mendes-Pinheiro B; Domingues AV; Vilaça-Faria H; Marote A; Silva D; Sousa RA; Salgado AJ
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32422916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease.
    Kirik D; Georgievska B; Rosenblad C; Björklund A
    Eur J Neurosci; 2001 Apr; 13(8):1589-99. PubMed ID: 11328352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats.
    Pang Y; Lin S; Wright C; Shen J; Carter K; Bhatt A; Fan LW
    Neuroscience; 2016 Mar; 318():157-65. PubMed ID: 26777890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining.
    Ares-Santos S; Granado N; Espadas I; Martinez-Murillo R; Moratalla R
    Neuropsychopharmacology; 2014 Apr; 39(5):1066-80. PubMed ID: 24169803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
    Rosenblad C; Kirik D; Devaux B; Moffat B; Phillips HS; Björklund A
    Eur J Neurosci; 1999 May; 11(5):1554-66. PubMed ID: 10215908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.